Questions to ask a clinician about peptides: a checklist for your next appointment

By · Published · 6 min read · 9 sources, 9 checked at the source

Four cards titled Status (approved, compounded or neither), Compounding (licensed pharmacy, one named patient), Evidence (human studies, trials, tracking) and Cost (coverage and the all-in price).

More people are bringing peptides up with their doctors, and more clinicians are open to the conversation, especially since HHS's new compounding policy for six peptides. A short appointment goes faster when the questions are written down before you walk in. FDA publishes its own list of questions for patients considering an off-label prescription, and the federal health-research agency AHRQ has a free tool for building a question list. This checklist builds on both and adds the questions specific to peptides: approval status, compounding, research and cost. Each section explains the background, and the full checklist, ready to print, follows them.

Facts are as of October 30, 2026. Sources, with retrieval dates, are at the bottom.

The gist

  • FDA's off-label page lists seven questions patients may want to ask, from what a drug is approved for to whether insurance will pay and whether a trial is open. [V]
  • AHRQ's free QuestionBuilder app and website let patients pick or write questions and save them to a calendar appointment or email. [V]
  • For the six peptides in HHS's October 2026 policy, the questions turn on the policy's conditions: a state-licensed pharmacy, a prescription for one named patient, and an ingredient from an FDA-registered facility with a certificate of analysis. [V]
  • The questions below are ours, grouped by topic, and none of them asks for a specific product. They help the conversation start from facts.
  • 7questions on FDA's own off-label checklist for patients [V]
  • 6peptides covered by HHS's compounding enforcement policy [V]
  • 3steps in AHRQ's QuestionBuilder: download, pick questions, save them [V]

Start with the tools the government already offers

FDA's page on off-label use has a short section called "Questions you may want to consider." It suggests asking what a drug is approved for, whether approved alternatives exist, what studies support the use, how it compares with an approved treatment, what the benefits and risks are, whether insurance will cover it, and whether there's a trial you could join. [V] Those seven questions were written for approved drugs used in new ways, but most of them carry over to peptides. [S]

The Agency for Healthcare Research and Quality (AHRQ), part of HHS, runs a program called Questions Are the Answer. Its QuestionBuilder app is free on Apple and Google stores and online. AHRQ says it lets people sort questions by type of visit, photograph items like insurance cards or pill bottles, and save the list to a calendar entry or email. [V] AHRQ also says nothing typed into the app is stored by the app itself. [V]

Status: approved, compounded or neither

Peptides span a wide range, from FDA-approved medicines like semaglutide and tesamorelin to substances with no approved product. [V] Knowing which group a peptide falls into tells you which path is even possible. Our approved vs wellness peptides table sorts the common names.

For athletes, status has a second meaning. WADAWorld Anti-Doping Agency: it publishes the yearly Prohibited List for tested sport. Glossary entry, the NCAA and pro leagues keep their own lists of banned substances, separate from FDA's rules, and we line them up in our sport rules guide. [V]

Compounding: what HHS's policy expects

FDA's compounding Q&A says compounded drugs are not FDA-approved and can meet a real need when an approved drug isn't medically appropriate for a patient. [V] HHS's policy describes itself as a way to expand patient access, and its conditions spell out what the agency expects. The pharmacy must be state-licensed, the prescription must be for an identified patient, and the ingredient must come from an FDA-registered facility with a valid certificate of analysis. [V]

Our compounding categories explainer and 503A bulks list guide cover the rules behind these questions.

Evidence: where the research stands

Research on many wellness peptides is at an early stage, and much of it is in animals. [V] A clinician who has followed the literature can explain where a peptide sits, and our evidence ladder shows the rungs.

FDA's off-label list also asks about trials. [V] Our guide on how to read a trial listing explains what a ClinicalTrials.gov record does and doesn't tell you.

Cost and coverage

FDA's off-label checklist includes asking whether insurance will cover the treatment. [V] Federal Medicaid and Medicare Part D definitions are built around approved drugs, which helps explain why compounded peptides are usually paid for out of pocket. [V] Our doctors and insurance explainer walks through it.

Peptide Policy Watch

Questions to ask a clinician about peptides: a checklist for your next appointment

Published October 30, 2026 · https://peptidepolicywatch.com/2026/10/30/questions-to-ask-your-clinician-about-peptides/

Printable checklist

Questions for your clinician

General questions drawn from this page, to take to a clinician or pharmacist who knows your health history.

Status

  1. Is there an FDA-approved product with this ingredient, and what is it approved for?
  2. If there isn't, would this have to be compounded by a pharmacy?
  3. Is this peptide one of the six in HHS's October 2026 compounding policy, or in one of FDA's interim categories?
  4. Is it on an anti-doping list that matters for me or my child's sport?

Compounding

  1. Which pharmacy would make it, and is it licensed in our state?
  2. Does the pharmacy follow the conditions in HHS's policy, including a certificate of analysis for the ingredient?
  3. If a question or a problem comes up later, who do I call: your office or the pharmacy?
  4. Is there an approved alternative you would consider first, and why or why not?

Evidence

  1. What human studies exist for this peptide, and how large were they?
  2. Have you seen results in your own patients, and how do you track them?
  3. What would tell us it's working, and when would we check?
  4. Is there a registered clinical trial I could ask about?

Cost

  1. Would my plan cover any of this, and who can check?
  2. What does a visit, a prescription and a refill cost, all in?
  3. If I join a trial, what costs would it cover?

Print view Select it, then use your browser’s Print command to print only this box.

When a clinician says no

Many clinicians who are interested in peptides still work within limits set by approval status, state pharmacy rules, employer policies and insurance. [S] A "no" can reflect those rules rather than a view of the science. Asking "Is that a rule, or your clinical view?" can tell you which. [S] If the answer is a rule, the HHS comment window, open until 11:59 PM Eastern on November 13, 2026, is one place where patients and practitioners can put their views on the record. [V]

Limits and unknowns

  • These questions are editorial. Neither FDA nor AHRQ wrote a peptide-specific checklist. [V]
  • AHRQ's QuestionBuilder page was last reviewed in June 2022. Its app-store listings may have changed since. [U]
  • We don't know how many state pharmacy boards have issued guidance on HHS's policy. [U]

Sources (retrieved October 30, 2026 unless noted)

  1. FDA, "Understanding Unapproved Use of Approved Drugs 'Off Label'," content current as of February 5, 2018 [V] — https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/understanding-unapproved-use-approved-drugs-label
  2. AHRQ, "QuestionBuilder App," content last reviewed June 2022 [V] — https://www.ahrq.gov/questions/question-builder/index.html
  3. AHRQ, "Questions Are the Answer" [V] — https://www.ahrq.gov/questions/index.html
  4. FDA, "Compounding and the FDA: Questions and Answers," content current as of September 16, 2025 [V] — https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
  5. HHS, "Enforcement Discretion Policy Regarding 503ASection of federal drug law covering compounding by state-licensed pharmacies and doctors, usually for a prescription written for one patient. Glossary entry Compounding Using Certain Peptide Bulk Drug Substances," with Appendices A and B [V] — https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
  6. Regulations.gov, docket HHS-OASH-2026-0496 [V] — https://www.regulations.gov/docket/HHS-OASH-2026-0496
  7. 42 U.S.C. 1396r-8, via Cornell Legal Information Institute [V] — https://www.law.cornell.edu/uscode/text/42/1396r-8
  8. eCFR, 42 CFR 423.100, Part D definitions [V] — https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-B/part-423/subpart-A/section-423.100
  9. Systematic review of BPC-157 research, HSS Journal, 2025 (PubMed) [V] — https://pubmed.ncbi.nlm.nih.gov/40756949/

Spot a mistake? See how we source and our corrections policy.